<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Etiology of the Budd-Chiari syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Etiology of the Budd-Chiari syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Etiology of the Budd-Chiari syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Lai, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The Budd-Chiari syndrome can be defined as any pathophysiologic process that results in an interruption or diminution of the normal flow of blood out of the liver [<a href="#rid1">1,2</a>]. However, as commonly used, the Budd-Chiari syndrome implies thrombosis of the hepatic veins and/or the intrahepatic or suprahepatic inferior vena cava. An alternative nomenclature that recognizes an obliterative process involving principally the inferior vena cava ("obliterative hepatocavopathy") has also been proposed [<a href="#rid3">3</a>]. The term is usually distinguished from two other conditions that interfere with hepatic venous flow: sinusoidal obstruction syndrome (hepatic veno-occlusive disease) and right heart failure.</p><p class="bulletIndent1"><span class="glyph">●</span>Disorders that involve the microscopic centrilobular veins and small sublobular veins within the liver are usually due to nonthrombotic fibrous occlusion and obliteration of these small veins. The distinct anatomic location, pathology, and conditions (eg, ingestion of toxic pyrrolizidine alkaloids or exposure to high doses of radiation or chemotherapeutic agents) with which sinusoidal obstruction syndrome is associated allow it to be placed in its own category [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although disorders of the heart may present clinically as the Budd-Chiari syndrome (eg, constrictive pericarditis, chronic right-sided heart failure with severe tricuspid insufficiency), the pathogenesis and treatment of these disorders are quite different from those usually considered typical of the Budd-Chiari syndrome. (See  <a class="medical medical_review" href="/z/d/html/3592.html" rel="external">"Congestive hepatopathy"</a>.)</p><p></p><p>Thus, the Budd-Chiari syndrome is due to occlusion or partial occlusion of one, two, or all three of the major hepatic veins (right, middle, and left) and/or occlusion or partial occlusion of the inferior vein cava  (<a class="graphic graphic_figure graphicRef81897" href="/z/d/graphic/81897.html" rel="external">figure 1</a>) [<a href="#rid6">6</a>]. In addition, several small veins that enter the inferior vena cava directly from the posterior surface of the caudate lobe and occasionally from the right and left hepatic lobes may or may not be involved by the occlusive process.</p><p>This topic review will discuss the major causes of the Budd-Chiari syndrome. The symptoms, diagnosis, and treatment of this disorder are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3562.html" rel="external">"Budd-Chiari syndrome: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>An underlying disorder can be identified in over 80 percent of patients with the Budd-Chiari syndrome [<a href="#rid7">7-14</a>]. More than one thrombotic risk factor is present in many patients; 46 percent had more than one risk factor in one series [<a href="#rid14">14</a>]. Many of these disorders are characterized by a hypercoagulable state, which is important to consider when treating Budd-Chiari syndrome (eg, the importance of anticoagulation after endovascular intervention)  (<a class="graphic graphic_table graphicRef130488" href="/z/d/graphic/130488.html" rel="external">table 1</a>). An evaluation for acquired and inherited thrombotic conditions is generally performed for patients with Budd-Chiari syndrome, and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3562.html" rel="external">"Budd-Chiari syndrome: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Myeloproliferative disorders</span><span class="headingEndMark"> — </span>As many as 50 percent of all cases of the Budd-Chiari syndrome may be due to an underlying chronic myeloproliferative disorder (eg, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia) and an accompanying hypercoagulable state. Peripheral blood evidence for myeloproliferation may not be present if portal hypertension, splenomegaly, and a hypersplenic state accompany the Budd-Chiari syndrome.</p><p>The combination of a myeloproliferative disorder (occult or overt) associated with a hypercoagulable state (or states) is common [<a href="#rid14">14-17</a>]. In one of the largest published series (involving 237 patients evaluated at four centers between 1984 and 2001), 23 percent had an overt myeloproliferative disorder (polycythemia vera in 45 patients and essential thrombocytosis in 9 patients) [<a href="#rid18">18</a>]. In another large series, 49 percent of 103 patients who underwent testing had a myeloproliferative disorder, the most common of which was polycythemia vera [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a>.)</p><p>Spontaneous erythroid colony formation in the presence of low serum erythropoietin levels, increased megakaryocyte colony growth, and clonal karyotypic abnormalities have all been reported in patients with Budd-Chiari syndrome due to myeloproliferative disorders [<a href="#rid19">19</a>] and in some so-called "idiopathic" cases of Budd-Chiari syndrome, suggesting the presence of an occult myeloproliferative syndrome in these persons [<a href="#rid15">15,16,20-23</a>]. In one study, for example, spontaneous endogenous erythroid colony formation in vitro and/or bone marrow biopsies suggested that a primary myeloproliferative disorder was present in 78 percent of such patients [<a href="#rid22">22</a>].</p><p><em>JAK2 </em>tyrosine kinase (V617F) mutations have been described in 26 to 59 percent of patients with Budd-Chiari syndrome, many of whom had negative results from standard testing for myeloproliferative disorders [<a href="#rid14">14,17,23-25</a>]. A <em>JAK2</em> mutation is present in almost all patients with polycythemia vera and approximately 50 percent of patients with essential thrombocythemia or chronic idiopathic myelofibrosis. One report described Budd-Chiari syndrome associated with hypereosinophilic syndrome and a <em>JAK2</em> mutation [<a href="#rid26">26</a>]. We suggest that patients diagnosed with Budd-Chiari syndrome in whom no underlying disorder can be identified be tested for a <em>JAK2</em> mutation. (See  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms", section on 'Mutations in PV, ET, and PMF'</a>.)</p><p>Interestingly, some data suggest that the liver may produce erythropoietin during the acute phase of Budd-Chiari syndrome [<a href="#rid27">27</a>]. Such a change could contribute to the apparent spontaneous erythroid colony formation in cultured bone marrow or peripheral blood mononuclear cells demonstrated in these patients.</p><p class="headingAnchor" id="H4"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>Malignancies account for approximately 10 percent of cases of the Budd-Chiari syndrome. Direct compression or invasion of vascular structures and the hypercoagulable state associated with malignancy can result in venous thrombosis and/or obstruction (see  <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>). Hepatocellular carcinomas are found most often, followed by cancer of the adrenal gland or kidney, sarcomas of the right atrium, inferior vena cava or hepatic veins, and cancers of the lung, pancreas, and stomach [<a href="#rid9">9</a>]. Hepatocellular carcinoma has also been associated with membranous obstruction of the inferior vena cava, another cause of Budd-Chiari syndrome. (See <a class="local">'Membranous webs'</a> below and  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Infections and benign lesions of the liver</span><span class="headingEndMark"> — </span>Infections or benign space-occupying lesions of the liver can, like tumors, compress and/or thrombose vascular structures, accounting for nearly 10 percent of cases of Budd-Chiari syndrome. Some of these disorders also may be accompanied by a hypercoagulable state. These lesions include hepatic cysts and abscesses, hepatic adenoma, hepatic mucinous cystic neoplasm (cystadenoma), syphilitic gumma, invasive aspergillosis, zygomycosis (mucormycosis), and aortic aneurysm [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Oral contraceptives and pregnancy</span><span class="headingEndMark"> — </span>Nearly 20 percent of cases of the Budd-Chiari syndrome occur in women who have been on oral contraceptives (for as little as two weeks), are pregnant, or have delivered a child within the previous two months [<a href="#rid28">28-32</a>]. It is presumed that the hypercoagulable state in these women is responsible for this association. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Other hypercoagulable states</span><span class="headingEndMark"> — </span>A number of other hypercoagulable states have been associated with the Budd-Chiari syndrome. These include [<a href="#rid33">33,34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>G1691A factor V (Leiden) gene mutation, which produces activated protein C resistance [<a href="#rid35">35-39</a>] (see  <a class="medical medical_review" href="/z/d/html/1355.html" rel="external">"Factor V Leiden and activated protein C resistance"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>G20210A factor II gene mutation [<a href="#rid40">40</a>] (see  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Antiphospholipid syndrome [<a href="#rid41">41-45</a>] (see  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Antithrombin deficiency [<a href="#rid46">46,47</a>] (see  <a class="medical medical_review" href="/z/d/html/1360.html" rel="external">"Antithrombin deficiency"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Protein C deficiency [<a href="#rid48">48-50</a>] (see  <a class="medical medical_review" href="/z/d/html/1354.html" rel="external">"Protein C deficiency"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Protein S deficiency (see  <a class="medical medical_review" href="/z/d/html/1357.html" rel="external">"Protein S deficiency"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Paroxysmal nocturnal hemoglobinuria [<a href="#rid51">51,52</a>] (see  <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">"Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"</a>)</p><p></p><p>The factor V Leiden mutation, the most frequent cause of hereditary thrombophilia, may be particularly important. This mutation was present in approximately 25 percent of patients in three series that included a total of 126 patients [<a href="#rid37">37,53,54</a>]. A systematic review and meta-analysis of observational studies in Budd-Chiari syndrome found that inherited deficiencies of antithrombin, protein C, and protein S were rare (2.3, 3.8, and 3 percent, respectively) [<a href="#rid55">55</a>].</p><p>The likelihood of thrombosis may be greatest when the factor V Leiden mutation occurs in combination with another predisposing disorder or condition such as pregnancy, the administration of oral contraceptives, or a myeloproliferative syndrome [<a href="#rid35">35,56</a>]. (See  <a class="medical medical_review" href="/z/d/html/1355.html" rel="external">"Factor V Leiden and activated protein C resistance"</a>.)</p><p>That the interaction of one or more predisposing conditions may coexist was also supported in a study that included 32 patients with Budd-Chiari syndrome in whom the presence of most of the known prothrombotic conditions was investigated [<a href="#rid57">57</a>]. A myeloproliferative disorder was detected in 17 patients of whom 7 (41 percent) also had one or more prothrombotic coagulation disorders. Of 11 other patients without a myeloproliferative disorder, 9 had a single prothrombotic coagulation disorder (82 percent). The G20210A factor II gene mutation was observed in 2 of 32 patients (6 percent) with Budd-Chiari syndrome and in 5 of 36 patients (14 percent) with protal vein thrombosis. Among healthy controls, the mutation is seen in 1 to 5 percent of patients [<a href="#rid58">58-61</a>]. The prevalence of homozygous C677TMTHFR (methylene-tetrahydrofolate-reductase) gene mutation was 12.5 percent, which was similar to the healthy controls (approximately 10 percent).</p><p>In one of the studies described above [<a href="#rid53">53</a>], the presence of combined (acquired and inherited) risk factors was 25, 49, 19, and 7 percent of the group having zero, one, two, or three risk factors, respectively [<a href="#rid53">53</a>].</p><p>Additional prothrombotic conditions that may contribute to venous thrombosis (such as high levels of factor XI) continue to be described [<a href="#rid62">62</a>]. Whether they are associated with the Budd-Chiari syndrome requires further investigation. A single case-control study suggests that impaired fibrinolysis, partially caused by elevated plasminogen activator inhibitor 1 levels, may play a role in the pathogenesis of Budd-Chiari syndrome [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Behçet syndrome</span><span class="headingEndMark"> — </span>Vasculitis is an important feature of Behçet syndrome (see  <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome"</a>). In one study of 493 cases, 53 had one or more large vessel thrombosis [<a href="#rid64">64</a>]. Fourteen of these 53 patients had hepatic vein thrombosis, eight also had inferior vena cava thrombosis, and two had both inferior vena cava and portal vein thrombosis. Only two patients had isolated hepatic vein thrombosis.</p><p class="headingAnchor" id="H9"><span class="h2">Membranous webs</span><span class="headingEndMark"> — </span>Membranous obstruction (partial or complete) of the inferior vena cava (MOVC) and/or the hepatic veins is an unusual but potentially treatable cause of the Budd-Chiari syndrome in the United States [<a href="#rid65">65</a>], but it is much more common in South Africa, India, and Asia [<a href="#rid66">66,67</a>]. These web-like lesions, which usually are found just cephalad to the entrance of the right hepatic vein into the inferior vena cava, may be the result of a congenital anomaly. However, they are more often attributable to an acquired thrombotic process such as a myeloproliferative disease [<a href="#rid68">68,69</a>]. MOVC has also been associated with the subsequent development of hepatocellular carcinoma [<a href="#rid70">70,71</a>].</p><p>It is important to diagnose MOVC or so-called short-length hepatic vein stenoses [<a href="#rid72">72</a>] because of the availability of treatment options (eg, anticoagulation, angioplasty, or stenting) that are usually not germane to other causes of the Budd-Chiari syndrome.</p><p class="headingAnchor" id="H10"><span class="h2">Miscellaneous</span><span class="headingEndMark"> — </span>Miscellaneous associations with the Budd-Chiari syndrome include systemic lupus erythematosus, mixed-connective tissue disease, Sjögren's disease, inflammatory bowel disease, hypereosinophilic syndrome, idiopathic granulomatous venulitis, sarcoidosis, protein-losing enteropathy, minimal change nephrotic syndrome, neurofibromatosis, alpha-1 antitrypsin deficiency, trauma (including laparoscopic cholecystectomy) or torsion of the liver, and rare familial cases [<a href="#rid9">9,73</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Idiopathic</span><span class="headingEndMark"> — </span>Approximately 20 percent of cases of the Budd-Chiari syndrome are listed as idiopathic [<a href="#rid74">74</a>]. As more and more conditions which predispose to Budd-Chiari syndrome, such as occult myeloproliferative disease and factor V Leiden mutation, are recognized, the percentage of cases described as idiopathic will continue to decrease [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H12"><span class="h1">HEMODYNAMIC CONSEQUENCES</span><span class="headingEndMark"> — </span>Regardless of the cause, patients with Budd-Chiari syndrome develop postsinusoidal portal hypertension, which leads to complications similar to those observed in patients with cirrhosis. However, the systemic hemodynamic effects differ from those that are observed classically in patients with cirrhosis.</p><p>The most detailed study evaluated systemic and cardiopulmonary hemodynamics, plasma renin activity, aldosterone and norepinephrine levels, and plasma volume in patients with Budd-Chiari syndrome who were admitted for complications of portal hypertension [<a href="#rid75">75</a>]. Systemic, cardiopulmonary pressures, and cardiac indices in patients with Budd-Chiari syndrome were within the normal range for most patients, but were significantly different compared with a matched group of cirrhotic patients. Despite normal systemic vascular resistance, there was activation of the neurohumoral vasoactive systems and plasma volume expansion. Normal pressures were not observed in all patients; in approximately one-third (mostly those with longer duration of illness) systemic vascular resistance was decreased.</p><p class="headingAnchor" id="H2327782184"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119173.html" rel="external">"Society guideline links: Hepatic, portal, and splenic vein thrombosis"</a>.)</p><p class="headingAnchor" id="H365876928"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – The Budd-Chiari syndrome can be defined as any pathophysiologic process that results in an interruption or diminution of the normal flow of blood out of the liver.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – An underlying disorder can be identified in over 80 percent of patients with the Budd-Chiari syndrome. Many of these disorders are characterized by a hypercoagulable state, which is important to consider when treating the Budd-Chiari syndrome (eg, the importance of anticoagulation after endovascular intervention  (<a class="graphic graphic_table graphicRef130488" href="/z/d/graphic/130488.html" rel="external">table 1</a>). As a general rule, work-up should include hepatic imaging and evaluation for inflammatory, immunologic, and thrombotic disorders. (See  <a class="medical medical_review" href="/z/d/html/3562.html" rel="external">"Budd-Chiari syndrome: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a> and <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamic consequences</strong> – Regardless of the cause, patients with Budd-Chiari syndrome develop postsinusoidal portal hypertension, which leads to complications similar to those observed in patients with cirrhosis. However, the systemic hemodynamic effects differ from those that are observed classically in patients with cirrhosis. (See <a class="local">'Hemodynamic consequences'</a> above.) </p><p></p><p class="headingAnchor" id="H21341716"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Stephen C Hauser, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Valla DC. Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome. Gut 2008; 57:1469.</a></li><li><a class="nounderline abstract_t">Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004; 350:578.</a></li><li><a class="nounderline abstract_t">Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology 1998; 28:1191.</a></li><li><a class="nounderline abstract_t">Zafrani ES, von Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med 1983; 143:495.</a></li><li><a class="nounderline abstract_t">Baglin TP. Veno-occlusive disease of the liver complicating bone marrow transplantation. Bone Marrow Transplant 1994; 13:1.</a></li><li><a class="nounderline abstract_t">Saint-Marc Girardin MF, Zafrani ES, Prigent A, et al. Unilobar small hepatic vein obstruction: possible role of progestogen given as oral contraceptive. Gastroenterology 1983; 84:630.</a></li><li><a class="nounderline abstract_t">Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994; 73:21.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 51-1987. Progressive abdominal distention in a 51-year-old woman with polycythemia vera. N Engl J Med 1987; 317:1587.</a></li><li><a class="nounderline abstract_t">Mitchell MC, Boitnott JK, Kaufman S, et al. Budd-Chiari syndrome: etiology, diagnosis and management. Medicine (Baltimore) 1982; 61:199.</a></li><li><a class="nounderline abstract_t">Powell-Jackson PR, Melia W, Canalese J, et al. Budd-Chiari Syndrome: clinical patterns and therapy. Q J Med 1982; 51:79.</a></li><li><a class="nounderline abstract_t">Gupta S, Blumgart LH, Hodgson HJ. Budd-Chiari syndrome: long-term survival and factors affecting mortality. Q J Med 1986; 60:781.</a></li><li><a class="nounderline abstract_t">Murphy FB, Steinberg HV, Shires GT 3rd, et al. The Budd-Chiari syndrome: a review. AJR Am J Roentgenol 1986; 147:9.</a></li><li><a class="nounderline abstract_t">Maddrey WC. Hepatic vein thrombosis (Budd-Chiari syndrome). Hepatology 1984; 4:44S.</a></li><li><a class="nounderline abstract_t">Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151:167.</a></li><li><a class="nounderline abstract_t">Hirshberg B, Shouval D, Fibach E, et al. Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome. J Hepatol 2000; 32:574.</a></li><li><a class="nounderline abstract_t">Amitrano L, Guardascione MA, Ames PR, et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003; 72:75.</a></li><li><a class="nounderline abstract_t">Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44:1528.</a></li><li><a class="nounderline abstract_t">Darwish Murad S, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39:500.</a></li><li><a class="nounderline abstract_t">Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985; 103:329.</a></li><li><a class="nounderline abstract_t">Pagliuca A, Mufti GJ, Janossa-Tahernia M, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis--possible evidence of an occult myeloproliferative state. Q J Med 1990; 76:981.</a></li><li><a class="nounderline abstract_t">Acharya J, Westwood NB, Sawyer BM, et al. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol 1995; 55:315.</a></li><li><a class="nounderline abstract_t">De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23:411.</a></li><li><a class="nounderline abstract_t">Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130:2031.</a></li><li><a class="nounderline abstract_t">Qi X, Yang Z, Bai M, et al. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther 2011; 33:1087.</a></li><li><a class="nounderline abstract_t">Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120:4921.</a></li><li><a class="nounderline abstract_t">Mishchenko E, Tadmor T, Schiff E, et al. Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what? Am J Hematol 2011; 86:223.</a></li><li><a class="nounderline abstract_t">Levy VG, Ruskone A, Baillou C, et al. Polycythemia and the Budd-Chiari syndrome: study of serum erythropoietin and bone marrow erythroid progenitors. Hepatology 1985; 5:858.</a></li><li><a class="nounderline abstract_t">Valla D, Le MG, Poynard T, et al. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986; 90:807.</a></li><li><a class="nounderline abstract_t">Lewis JH, Tice HL, Zimmerman HJ. Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases. Dig Dis Sci 1983; 28:673.</a></li><li><a class="nounderline abstract_t">Lalonde G, Théoret G, Daloze P, et al. Inferior vena cava stenosis and Budd--Chiari syndrome in a woman taking oral contraceptives. Gastroenterology 1982; 82:1452.</a></li><li><a class="nounderline abstract_t">Khuroo MS, Datta DV. Budd-Chiari syndrome following pregnancy. Report of 16 cases, with roentgenologic, hemodynamic and histologic studies of the hepatic outflow tract. Am J Med 1980; 68:113.</a></li><li><a class="nounderline abstract_t">Perarnau JM, Bacq Y. Hepatic vascular involvement related to pregnancy, oral contraceptives, and estrogen replacement therapy. Semin Liver Dis 2008; 28:315.</a></li><li><a class="nounderline abstract_t">Shetty S, Ghosh K. Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis--a concise review. Thromb Res 2011; 127:505.</a></li><li><a class="nounderline abstract_t">Qi X, Han G, Guo X, et al. Review article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China. Aliment Pharmacol Ther 2016; 44:1152.</a></li><li><a class="nounderline abstract_t">Fickert P, Ramschak H, Kenner L, et al. Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation. Gastroenterology 1996; 111:1670.</a></li><li><a class="nounderline abstract_t">Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127:895.</a></li><li><a class="nounderline abstract_t">Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40:798.</a></li><li><a class="nounderline abstract_t">Hoffman R, Nimer A, Lanir N, et al. Budd-Chiari syndrome associated with factor V leiden mutation: a report of 6 patients. Liver Transpl Surg 1999; 5:96.</a></li><li><a class="nounderline abstract_t">Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12:1801.</a></li><li><a class="nounderline abstract_t">Laposata M. The prothrombin G20210A mutation: a new high-prevalence congenital risk factor for thrombosis. Gastroenterology 1999; 116:213.</a></li><li><a class="nounderline abstract_t">Saca LF, Szer IS, Henar E, et al. Budd-Chiari syndrome associated with antiphospholipid antibodies in a child: report of a case and review of the literature. J Rheumatol 1994; 21:545.</a></li><li><a class="nounderline abstract_t">Mackworth-Young CG, Melia WM, Harris EN, et al. The Budd-Chiari syndrome. Possible pathogenetic role of anti-phospholipid antibodies. J Hepatol 1986; 3:83.</a></li><li><a class="nounderline abstract_t">Van Steenbergen W, Beyls J, Vermylen J, et al. 'Lupus' anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome). Report of three patients and review of the literature. J Hepatol 1986; 3:87.</a></li><li><a class="nounderline abstract_t">Pomeroy C, Knodell RG, Swaim WR, et al. Budd-Chiari syndrome in a patient with the lupus anticoagulant. Gastroenterology 1984; 86:158.</a></li><li><a class="nounderline abstract_t">Espinosa G, Font J, García-Pagan JC, et al. Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients. Medicine (Baltimore) 2001; 80:345.</a></li><li><a class="nounderline abstract_t">Das M, Carroll SF. Antithrombin III deficiency: an etiology of Budd-Chiari syndrome. Surgery 1985; 97:242.</a></li><li><a class="nounderline abstract_t">McClure S, Dincsoy HP, Glueck H. Budd-Chiari Syndrome and antithrombin III deficiency. Am J Clin Pathol 1982; 78:236.</a></li><li><a class="nounderline abstract_t">Sugano S, Suzuki T, Makino H, et al. Budd-Chiari syndrome attributed to protein C deficiency. Am J Gastroenterol 1996; 91:777.</a></li><li><a class="nounderline abstract_t">Majluf-Cruz A, Hurtado Monroy R, Sansores García L, Labardini-Méndez J. The incidence of protein C deficiency in thrombosis-related portal hypertension. Am J Gastroenterol 1996; 91:976.</a></li><li><a class="nounderline abstract_t">Bourlière M, Le Treut YP, Arnoux D, et al. Acute Budd-Chiari syndrome with hepatic failure and obstruction of the inferior vena cava as presenting manifestations of hereditary protein C deficiency. Gut 1990; 31:949.</a></li><li><a class="nounderline abstract_t">Valla D, Dhumeaux D, Babany G, et al. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome. Gastroenterology 1987; 93:569.</a></li><li><a class="nounderline abstract_t">Carmelo Gurnari, Ceylan Colak, Misam Zawit, Jaroslaw P Maciejewski. Chronic Budd–Chiari syndrome in paroxysmal nocturnal haemoglobinuria. The Lancet 2021; 398:e14.</a></li><li><a class="nounderline abstract_t">Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96:2364.</a></li><li><a class="nounderline abstract_t">Mohanty D, Shetty S, Ghosh K, et al. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology 2001; 34:666.</a></li><li><a class="nounderline abstract_t">Qi X, De Stefano V, Wang J, et al. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol 2013; 28:432.</a></li><li><a class="nounderline abstract_t">Deltenre P, Denninger MH, Hillaire S, et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001; 48:264.</a></li><li><a class="nounderline abstract_t">Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31:587.</a></li><li><a class="nounderline abstract_t">Schafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994; 344:1739.</a></li><li><a class="nounderline abstract_t">Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698.</a></li><li><a class="nounderline abstract_t">Chamouard P, Pencreach E, Maloisel F, et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999; 116:144.</a></li><li><a class="nounderline abstract_t">Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G--&gt;A20210 gene variant. Ann Intern Med 1998; 129:89.</a></li><li><a class="nounderline abstract_t">Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342:696.</a></li><li><a class="nounderline abstract_t">Hoekstra J, Guimarães AH, Leebeek FW, et al. Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood 2010; 115:388.</a></li><li><a class="nounderline abstract_t">Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Behçet's disease. Am J Gastroenterol 1997; 92:858.</a></li><li><a class="nounderline abstract_t">Rector WG Jr, Xu YH, Goldstein L, et al. Membranous obstruction of the inferior vena cava in the United States. Medicine (Baltimore) 1985; 64:134.</a></li><li><a class="nounderline abstract_t">Simson IW. Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in South Africa. Gastroenterology 1982; 82:171.</a></li><li><a class="nounderline abstract_t">Wang ZG. Budd-Chiari syndrome. 430 case experiences. Asian J Surg 1996; 19:23.</a></li><li><a class="nounderline abstract_t">Sevenet F, Deramond H, Hadengue A, et al. Membranous obstruction of the inferior vena cava associated with a myeloproliferative disorder: a clue to membrane formation? Gastroenterology 1989; 97:1019.</a></li><li><a class="nounderline abstract_t">Gwon D 2nd, Ko GY, Yoon HK, et al. Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE. Radiology 2010; 254:617.</a></li><li><a class="nounderline abstract_t">Lu CL, Chou YH, Hwang SJ, et al. Membranous obstruction of inferior vena cava in Taiwan. J Gastroenterol Hepatol 1995; 10:287.</a></li><li><a class="nounderline abstract_t">Matsui S, Ichida T, Watanabe M, et al. Clinical features and etiology of hepatocellular carcinoma arising in patients with membranous obstruction of the inferior vena cava: in reference to hepatitis viral infection. J Gastroenterol Hepatol 2000; 15:1205.</a></li><li><a class="nounderline abstract_t">Valla D, Hadengue A, el Younsi M, et al. Hepatic venous outflow block caused by short-length hepatic vein stenoses. Hepatology 1997; 25:814.</a></li><li><a class="nounderline abstract_t">Young ID, Clark RN, Manley PN, et al. Response to steroids in Budd-Chiari syndrome caused by idiopathic granulomatous venulitis. Gastroenterology 1988; 94:503.</a></li><li><a class="nounderline abstract_t">Garcia-Pagán JC, Valla DC. Primary Budd-Chiari Syndrome. N Engl J Med 2023; 388:1307.</a></li><li><a class="nounderline abstract_t">Hernández-Guerra M, López E, Bellot P, et al. Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology 2006; 43:27.</a></li></ol></div><div id="topicVersionRevision">Topic 3624 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18583397" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14762185" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9794901" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6338851" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Drug-induced vascular lesions of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8019444" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Veno-occlusive disease of the liver complicating bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6822331" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Unilobar small hepatic vein obstruction: possible role of progestogen given as oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8309360" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3683493" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 51-1987. Progressive abdominal distention in a 51-year-old woman with polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7045569" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Budd-Chiari syndrome: etiology, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7051086" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Budd-Chiari Syndrome: clinical patterns and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3774961" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Budd-Chiari syndrome: long-term survival and factors affecting mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2940846" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Budd-Chiari syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6693073" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hepatic vein thrombosis (Budd-Chiari syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19652186" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Etiology, management, and outcome of the Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10782905" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12555209" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133457" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14768004" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4026081" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2236481" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis--possible evidence of an occult myeloproliferative state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7493678" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9387199" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16762626" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21395632" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23043069" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21264914" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4029896" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Polycythemia and the Budd-Chiari syndrome: study of serum erythropoietin and bone marrow erythroid progenitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3949113" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6872799" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7067964" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Inferior vena cava stenosis and Budd--Chiari syndrome in a woman taking oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7350798" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Budd-Chiari syndrome following pregnancy. Report of 16 cases, with roentgenologic, hemodynamic and histologic studies of the hepatic outflow tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18814084" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hepatic vascular involvement related to pregnancy, oral contraceptives, and estrogen replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20961602" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis--a concise review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27734511" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Review article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8942748" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9382368" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9245936" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071347" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Budd-Chiari syndrome associated with factor V leiden mutation: a report of 6 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24793031" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869621" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The prothrombin G20210A mutation: a new high-prevalence congenital risk factor for thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8006900" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Budd-Chiari syndrome associated with antiphospholipid antibodies in a child: report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3091679" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The Budd-Chiari syndrome. Possible pathogenetic role of anti-phospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3091680" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : 'Lupus' anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome). Report of three patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6416918" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Budd-Chiari syndrome in a patient with the lupus anticoagulant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704712" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3969629" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antithrombin III deficiency: an etiology of Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7102823" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Budd-Chiari Syndrome and antithrombin III deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8677948" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Budd-Chiari syndrome attributed to protein C deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633591" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The incidence of protein C deficiency in thrombosis-related portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2387522" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acute Budd-Chiari syndrome with hepatic failure and obstruction of the inferior vena cava as presenting manifestations of hereditary protein C deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3609666" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chronic Budd–Chiari syndrome in paroxysmal nocturnal haemoglobinuria</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11001884" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11584361" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23216127" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11156651" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Factor V Leiden related Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706547" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7997003" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hypercoagulable states: molecular genetics to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8916933" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869612" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Frequent factor II G20210A mutation in idiopathic portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669991" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Increased risk for venous thrombosis in carriers of the prothrombin G--&gt;A20210 gene variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706899" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : High levels of coagulation factor XI as a risk factor for venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965669" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149201" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Budd-Chiari syndrome: a common complication of Behçet's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3871892" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Membranous obstruction of the inferior vena cava in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6274728" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Budd-Chiari syndrome. 430 case experiences</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2777025" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Membranous obstruction of the inferior vena cava associated with a myeloproliferative disorder: a clue to membrane formation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093533" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7548805" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Membranous obstruction of inferior vena cava in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11106103" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical features and etiology of hepatocellular carcinoma arising in patients with membranous obstruction of the inferior vena cava: in reference to hepatitis viral infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9096581" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hepatic venous outflow block caused by short-length hepatic vein stenoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3335322" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Response to steroids in Budd-Chiari syndrome caused by idiopathic granulomatous venulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37018494" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Primary Budd-Chiari Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374846" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
